Peritoneal metastases of rare carcinomas treated with cytoreductive surgery and HIPEC – A single center case series
Conclusion For patients with rare tumors, CRS and HIPEC is feasible with an acceptable perioperative morbidity and mortality. To improve knowledge in patient selection and outcome, rare tumors treated with CRS and HIPEC should be documented in central databases (as for example BIG RENAPE, Pierre-Benite, France).
Source: Annals of Medicine and Surgery - Category: General Medicine Source Type: research
More News: Adenocarcinoma | Appendicitis | Asbestosis | Brain | Cancer | Cancer & Oncology | Carcinoma | Carcinoma of Unknown Primary | Chemotherapy | Colon Cancer | Colorectal Cancer | Databases & Libraries | France Health | Gastric (Stomach) Cancer | Gastroenterology | General Medicine | Mesothelioma | Neurology | Neurosurgery | Ovarian Cancer | Ovaries | Peritoneal Cancer | Rare Diseases | Sarcomas | Study